Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Sana Biotechnology, Inc. (SANA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.93-0.33 (-5.27%)
At close: 04:00PM EDT
5.64 -0.29 (-4.89%)
After hours: 04:12PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close6.26
Open6.11
Bid5.60 x 2900
Ask8.50 x 1100
Day's Range5.65 - 6.38
52 Week Range3.92 - 23.50
Volume1,132,105
Avg. Volume1,339,119
Market Cap1.12B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Sana Biotechnology to Present at September 2022 Investor Conferences

    SEATTLE, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentations at two investor conferences in September. The presentations will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer. Sana will present at the Morgan Stanley 20th Annual Global Healthcare Conference at 2:55 p.m. ET on Tuesday, September

  • GlobeNewswire

    Sana Biotechnology Reports Second Quarter 2022 Financial Results and Business Updates

    Expect cash runway into 2025, enabling multiple data readouts across platforms for lead programs, driven by significant cash savings from manufacturing facility move to Bothell, Washington as well as research prioritization Expect to file INDs this year for SC291 and SG295 Presented preclinical data showing survival of transplanted hypoimmune allogeneic pancreatic islet cells, cardiomyocytes, and retinal pigment epithelium cells without immunosuppression in non-human primates Q2 2022 cash positi

  • GlobeNewswire

    Sana Biotechnology Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derived Differentiated Cell Types Without Immunosuppression in Non-Human Primates

    First demonstration of the survival of allogeneic islet cells, cardiomyocytes, and retinal pigment epithelium cells transplanted into an immunocompetent non-human primate model without any immune suppression The islet autoimmune data suggest that cells with hypoimmune (HIP) edits evade allogeneic immune response and autoimmune response in a type 1 diabetes mouse model Transplanting allogeneic cells into a non-human primate without immune suppression represents a key step toward development of en

Advertisement
Advertisement